All the news

Leaders of liver disease associations from Europe, the United States, Latin America and Asia issued a global call to action at the AASLD Liver Meeting this week in Boston, aiming to advance ...

An experimental therapeutic vaccine called NASVAC, which targets two different hepatitis B virus (HBV) antigens, led to a reduction in hepatitis B surface antigen (HBsAg) levels, according to study presented this week ...

A pair of experimental therapies for non-alcoholic steatohepatitis (NASH) failed to offer notable improvements in controlled clinical trials, despite having shown promising effects on liver biomarkers in earlier studies. Dr Stephen Harrison ...

Direct-acting antiviral treatment for hepatitis C need not be delayed until the completion of treatment for hepatocellular carcinoma (HCC; liver cancer), but people with hepatitis C need to be warned of a ...

Treatment with tesamorelin, a synthetic growth hormone-releasing hormone, reduced liver fat content and reduced the progression of liver fibrosis in people with HIV who had non-alcoholic fatty liver disease (NAFLD), researchers report ...

Sci-B-Vac, an investigational vaccine that contains three different hepatitis B virus (HBV) proteins, may offer more protection, especially for older adults, than widely used existing vaccine options, according to late-breaking study results presented ...

An experimental two-part vaccine was not able to prevent chronic hepatitis C virus (HCV) infection in a mid-stage study, according to a presentation at the recent IDWeek 2019 conference in Washington, DC. Prof. Andrea ...

Seventy-eight per cent of people using needle and syringe programmes in community pharmacies in London who opted to test for hepatitis C would prefer to receive their hepatitis C treatment from the ...

Obesity without non-alcoholic fatty liver disease (NAFLD) does not raise the risk of cancer, but people with NAFLD who are also obese are almost twice as likely to be diagnosed with cancer ...

People with HIV and hepatitis C co-infection who had fatty liver disease were twice as likely to die during a five-year follow-up period as their counterparts without fatty liver disease, ...